Establishment Labs (NASDAQ:ESTA) Price Target Raised to $103.00

by · The Cerbat Gem

Establishment Labs (NASDAQ:ESTA – Get Free Report) had its price objective hoisted by equities research analysts at BTIG Research from $96.00 to $103.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 30.30% from the company’s current price.

Several other research firms have also weighed in on ESTA. Needham & Company LLC raised their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen raised their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Mizuho raised their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Citigroup increased their price target on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average target price of $96.50.

Check Out Our Latest Report on Establishment Labs

Establishment Labs Price Performance

NASDAQ:ESTA traded down $12.20 during mid-day trading on Thursday, reaching $79.05. The stock had a trading volume of 1,034,808 shares, compared to its average volume of 551,048. Establishment Labs has a 12 month low of $33.35 and a 12 month high of $97.59. The stock has a market capitalization of $2.33 billion, a PE ratio of -53.05 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a 50-day simple moving average of $86.17 and a two-hundred day simple moving average of $74.15.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The business had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.57) earnings per share. On average, equities analysts anticipate that Establishment Labs will post -1.07 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Hedge funds have recently modified their holdings of the business. Simplify Asset Management Inc. raised its position in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after purchasing an additional 34,946 shares during the last quarter. Sigma Planning Corp increased its stake in shares of Establishment Labs by 325.5% in the first quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock valued at $1,160,000 after buying an additional 15,624 shares during the period. SG Americas Securities LLC increased its stake in shares of Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after buying an additional 21,742 shares during the period. AlTi Global Inc. bought a new position in shares of Establishment Labs during the first quarter worth about $842,000. Finally, Union Square Park Capital Management LLC lifted its stake in shares of Establishment Labs by 16.7% in the first quarter. Union Square Park Capital Management LLC now owns 105,000 shares of the company’s stock worth $5,962,000 after acquiring an additional 15,000 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

(Get Free Report)

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

See Also